Clinical Trials of Regeneration for Periodontal Tissue

Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (Other)
Overall Status
Completed
CT.gov ID
NCT00221130
Collaborator
ArBlast Co.,Ltd. (Industry), Nagoya University (Other)
10
1
17
0.6

Study Details

Study Description

Brief Summary

Adult periodontitis is a chronic infective disease affecting the periodontium. Periodontitis induce the destruction of attachment apparatus of teeth, resulting in periodontal pocket formation and teeth loss. This study will test the safety and efficacy of alveolous bone reproduction by the transplantation of mixture named periodontium injectable gel for the adult periodontitis patients. Injectable gel is the mixture of ex-vivo cultured mesenchymal stem stem cells, ex-vivo cultured osteoblast-like cells differentiated from mesenchymal stem cells and scaffold (include, platelet rich plasma, human thrombin and calcium chloride).

Condition or Disease Intervention/Treatment Phase
  • Procedure: surgical operation of cell transplantation
Phase 1/Phase 2

Detailed Description

Periodontal disease is an infectious disease. Gingivitis and periodontitis are the 2 major forms of this. Their primary etiology is bacterial plaque, which can induce destruction of the periodontal apparatus. Gingivitis is inflammation of the gingival that does not result in clinical attachment loss. Periodontitis is inflammation of the gingival and is characterized by loss of connective tissue attachment and alveolar bone.

Therapeutic approaches for periodontitis are divided into two categories: 1) anti-infective treatment; 2) regenerative therapy.

Several surgical techniques have been developed to regenerate periodontal tissues including guided tissue regeneration, bone grafting, the use of enamel matrix derivative. However, these techniques are not reached for complete regeneration of the periodontium.

This study will test the safety and efficacy of alveolous bone reproduction by the transplantation of mixture named periodontium injectable gel for the adult periodontitis patients. Injectable gel is the mixture of ex-vivo cultured mesenchymal stem stem cells, ex-vivo cultured osteoblast-like cells differentiated from mesenchymal stem cells and scaffold (include, platelet rich plasma, human thrombin and calcium chloride).

Study Design

Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Trial of Regenerative Periodontal Tissue by Transplanting Mesenchymal Stem Cells and Osteoblast Cells - I, II Phase-
Study Start Date :
Jul 1, 2004
Study Completion Date :
Dec 1, 2005

Outcome Measures

Primary Outcome Measures

  1. Alveolar bone defect []

Secondary Outcome Measures

  1. Tooth mobility []

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 1.Patient with adult periodontitis. 2. There are 4mm or more pocket using . 3.There are ten existing tooth or more of the lower jaw. 4.The brushing instruction is received, and the plaque control is maintained excellently. 5.The recovery by an existing periodontal operation cannot be expected. 6.The age is from 35 to 60 years old. 7.Blood clot function is normal. 8.The liver function is normal. 9.The intention and the ability of going to hospital regularly are possessed. 10.Agreement by the document is obtained.
Exclusion Criteria:
  • 1.Patient who has acute symptom of periodontitis. 2.Patient that decayed tooth is on teeth or the next teeth to be treated. 3.Patient who has contracted diabetic or autoimmune disease. 4.Patient who has contracted infectious disease. 5.Patient who has contracted osteoporosis. 6.Patient who has smoking habit within six months before it registers. 7.Patient who is taking treatment of hypertension and/or epilepsy. 8.Patient who has pregnancy or doubt of pregnancy. 9.Patient who has heavy allergic disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Biomedical Research and Innovation Kobe Hyogo Pref. Japan 650-0047

Sponsors and Collaborators

  • Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
  • ArBlast Co.,Ltd.
  • Nagoya University

Investigators

  • Principal Investigator: Shunsuke Baba, D.D.S, PhD, Institute of Biomedical Research and Innovation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00221130
Other Study ID Numbers:
  • BRI PDT03-01
First Posted:
Sep 22, 2005
Last Update Posted:
Feb 9, 2009
Last Verified:
Feb 1, 2009
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2009